Abstract

GRANDA-LOBATO, P et al. Palmoplantar erythrodysesthesia after perioperative treatment with chemotherapy. Sanid. Mil. [online]. 2022, vol.78, n.4, pp.258-260.  Epub June 26, 2023. ISSN 1887-8571.  https://dx.doi.org/10.4321/s1887-85712022000400009.

Palmoplantar erythrodysesthesia is an adverse event associated with the administration of docetaxel and fluoropyrimidines. The activity of the enzyme dihydropyrimidine dehydrogenase (DPD) determines the rate of catabolism of 5-Fluorouracil (5-FU) and is subject to interindividual variability and genetic polymorphism. Therefore, patients with DPD deficiency present an increased risk of toxicity. We present the case of a patient treated with docetaxel, oxaliplatin and 5-FU (FLOT scheme) who presented moderate skin toxicity and who was suspected of DPD deficiency.

Keywords : Fluorouracil; Docetaxel; Dihydropyrimidine dehydrogenase deficiency; Palmoplantar erythrodysesthesia.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )